So I decided in favor of $ARQT decided. I think I already posted that one.

Yesterday's figures at $ARQT

Arcutis Biotherapeutics Inc. reported strong results for the fourth quarter of 2025, significantly beating earnings and revenue forecasts. The company reported earnings per share (EPS) of $0.13, beating the forecast of $0.08, a positive surprise of 62.5%. Revenue reached $129.5 million, 16.52% above expectations of $111.14 million. Following the announcement, Arcutis shares rose moderately by 0.26% in after-hours trading, indicating a cautiously positive market sentiment.

Key findings

• Arcutis reported a positive EPS surprise of 62.5%, with actual EPS of $0.13 versus guidance of $0.08.
• Revenue for Q4 2025 was $129.5 million, an increase of 84% year-over-year.
• The company achieved positive net income and operating cash flow earlier than expected.
• The share price rose slightly by 0.26% in after-hours trading.
• R&D and selling, general and administrative (SG&A) expenses increased significantly, reflecting continued investment in growth.

Business development

Arcutis Biotherapeutics showed a robust business performance in the fourth quarter of 2025 with a remarkable year-on-year revenue growth of 84%, largely driven by the success of its product ZORYVE. The company achieved a net income of $17.4 million, a significant improvement compared to a net loss of $10.8 million in Q4 2024. This marks a successful turnaround and underlines the company's growing market presence and operational efficiency.

Key financial figures

• Revenue: $129.5 million, an increase of 84% year-on-year.
• Earnings per share: $0.13, compared to a forecast of $0.08.
• Net income: $17.4 million, compared to a net loss of $10.8 million in Q4 2024
• Operating cash flow: Positive for Q4 2025, achieved ahead of plan.

Results compared to forecast

Arcutis exceeded expectations with EPS of $0.13, 62.5% above the forecast of $0.08. Revenue of $129.5 million also exceeded the forecast of $111.14 million, a positive surprise of 16.52%. This strong performance underlines the successful implementation of the company's growth strategy.

Market reaction

Following the announcement of the results, Arcutis' share price rose 0.26% to $27.05 in after-hours trading. Although the stock continues to trade within its 52-week range of $11.86 to $31.77, the modest increase indicates a cautiously optimistic reaction from investors, supported by the company's strong financial performance.

Outlook and forecast

Arcutis forecasts continued revenue growth in 2026, with forecasts pointing to further improvements in EPS in the coming quarters. The company plans to maintain a positive quarterly cash flow throughout the year despite ongoing investments in product development and commercialization.

Management commentary

CEO Frank Watanabe commented: "Our strong performance in the fourth quarter reflects the successful execution of our strategy and the growing demand for ZORYVE. We are committed to maintaining this momentum as we expand our product offering and market reach."

Risks and challenges

• Increased R&D and SG&A costs could impact profitability if sales growth slows.
• Potential market saturation and increasing competition in the dermatology sector.
• Macroeconomic pressures and supply chain disruptions could impact future performance.

Questions and answers

During the earnings call, analysts inquired about the sustainability of sales growth and the impact of increased costs. Executives emphasized their focus on strategic investments to drive long-term growth and maintain competitive advantage.

Thanks to its solid financial results and strategic initiatives, Arcutis Biotherapeutics is well positioned for future growth, despite potential challenges in maintaining its current course.

After I recently did well with 2 pharmaceutical/biotechnology stocks and the shares $NKTR (-5,41 %) and also $GPCR went through the roof, yesterday I added a new $ARQT a new stock into my portfolio yesterday. They are also active in the dermatological field (neurodermatitis), but already have a sales driver on the market. Further approvals are to follow this year, which will lead to an expansion of the user groups.

This is therefore not a short-term trading position. I intend to hold it for a little longer.

In my view, last night's figures were very good. Let's see what the market makes of them today.